Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 524 citing articles:

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 21, pp. 1923-1934
Open Access | Times Cited: 446
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Shi Qiu, Ying Cai, Hong Yao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 341
The Role of Inflammation in Cardiovascular Disease
Michael Y. Henein, Sergio Vancheri, Giovanni Longo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12906-12906
Open Access | Times Cited: 310
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Jan Borén, Marja‐Riitta Taskinen, Elias Björnson, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 9, pp. 577-592
Closed Access | Times Cited: 144
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis (2023) Vol. 31, Iss. 6, pp. 641-853
Open Access | Times Cited: 134
The dawn of a new era of targeted lipid-lowering therapies
Lâle Tokgözoğlu, Peter Libby
European Heart Journal (2021) Vol. 43, Iss. 34, pp. 3198-3208
Open Access | Times Cited: 105
Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis
Shichu Liang, Cui Wang, Jing Zhang, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 103
Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation
Pedro L. Valenzuela, Luís M. Ruilope, Alejandro Santos‐Lozano, et al.
European Heart Journal (2023) Vol. 44, Iss. 21, pp. 1874-1889
Closed Access | Times Cited: 101
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
Jeanine E. Roeters van Lennep, Lâle Tokgözoğlu, Lina Badimón, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4157-4173
Open Access | Times Cited: 85
Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4186-4195
Open Access | Times Cited: 76
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Brian A. Bergmark, Nicholas Marston, Thomas A Prohaska, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1770-1780
Closed Access | Times Cited: 72
Lipoprotein(a) Is Markedly More Atherogenic Than LDL
Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 3, pp. 385-395
Open Access | Times Cited: 71
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Robert S. Rosenson, Daniel Gaudet, Robert A. Hegele, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 10, pp. 913-925
Closed Access | Times Cited: 63
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Christie M. Ballantyne, Szilárd Vasas, Masoud Azizad, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 10, pp. 899-912
Closed Access | Times Cited: 61
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook
Vikrama Raja, Carlos Aguíar, Nasreen Al-Sayed, et al.
Atherosclerosis (2023) Vol. 383, pp. 117312-117312
Open Access | Times Cited: 60
Obesity and Dyslipidemia: A Review of Current Evidence
Jelena Vekić, Aleksandra Stefanović, Aleksandra Zeljković
Current Obesity Reports (2023) Vol. 12, Iss. 3, pp. 207-222
Closed Access | Times Cited: 58
Elevated LDL Triglycerides and Atherosclerotic Risk
Mie Balling, Shoaib Afzal, George Davey Smith, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 2, pp. 136-152
Open Access | Times Cited: 57
The Pharmacological Efficacy of Baicalin in Inflammatory Diseases
Yongqiang Wen, Shaobin Wang, Chenxu Zhao, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9317-9317
Open Access | Times Cited: 55
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Julia Brandts, Kausik K. Ray
Nature Reviews Cardiology (2023) Vol. 20, Iss. 9, pp. 600-616
Closed Access | Times Cited: 53
Disorders of Lipid Metabolism
Shireen Masood, O. Masood, Syed Faiz Mujtaba, et al.
(2024), pp. 77-100
Closed Access | Times Cited: 32
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Gerald F. Watts, Robert S. Rosenson, Robert A. Hegele, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 29
Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
Harold Bays, Carol F. Kirkpatrick, Kevin C. Maki, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 3, pp. e320-e350
Open Access | Times Cited: 25
Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis
Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi Polisetty, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity
Yimin Zhao, Zhenhuang Zhuang, Yueying Li, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
VLDL Biogenesis and Secretion: It Takes a Village
Willemien van Zwol, Bart van de Sluis, Henry N. Ginsberg, et al.
Circulation Research (2024) Vol. 134, Iss. 2, pp. 226-244
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top